SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
IMA

ImageneBio, Inc. (NASDAQ:IMA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$3.92+$0.00 (+0.00%)
 
Market cap
$48.8M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 27, 1998
Market Cap$48.83M-43.3%
Revenue (ttm)$0-100.0%
Net Income-$43.33M-1.4%
EPS-$3.11+84.1%
Shares Out12.46M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume44,335
Open$4.04
Previous Close$3.92
Day's Range$3.82 - $4.04
52-Week Range$3.00 - $7.60
Beta0.74
AnalystsBuy
Price Target$1.33(-66.07%)
Earnings DateMar 9, 2027
-2.55% (1D)
No price history available.

About IMA

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Address
12526 High Bluff Drive, Suite 345, San Diego, CA 92130, San Diego, CA, 92130, US
Market Cap
49 million
Employees
18
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$17.33K
Bought
$95.84K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From IMA’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
+0.00%
5 Days
+18.43%
1 Month
-3.21%
6 Months
-29.50%
1 Year
-43.27%

$IMA stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in IMA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by IMA's directors and management

Net Shares Purchased by Insiders−20k−10k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

IMA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New IMA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to IMA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in IMA

VTIVanguard Morningstar Total Stock Market ETF$855.46K
VXFVanguard Extended Market ETF$221.17K
IWCiShares Micro-Cap ETF$94.34K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from IMA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
85
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
1
Sells
2
Buy Value
$95.84K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.